Chicago, IL – According to filings with the U.S. Securities and Exchange Commission, Paragon Biosciences Emalex is raising $35,000,010.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jeffrey Aronin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Paragon Biosciences Emalex

Paragon solves complex human and societal challenges by creating and supporting focused, visionary companies that accelerate development of novel therapies and life science breakthroughs. Paragon Biosciences is a life science innovator, accelerating the development of revolutionary technologies, new medicines and breakthrough treatments. We are committed to creating, investing in and building life science companies that have the potential to solve some of the world’s greatest challenges. To do this, we have assembled an exceptional team comprised of industry experts, with decades of experience, who have proven track records of building and capitalizing businesses, earning FDA approvals and obtaining numerous patents.

To learn more about Paragon Biosciences Emalex, visit http://www.paragonbiosci.com/

Contact:
Jeffrey Aronin, Chief Executive Officer
312-847-1350
https://www.linkedin.com/in/jeffrey-aronin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved